Inflammatory Cytokines and Antipsychotic-Induced Weight Gain: Review and Clinical Implications

Trehani M. Fonseka\textsuperscript{a–c}, Daniel J. Müller\textsuperscript{c} and Sidney H. Kennedy\textsuperscript{a, b}

\textsuperscript{a} Department of Psychiatry, University Health Network, University of Toronto, \textsuperscript{b} Department of Psychiatry, St. Michael’s Hospital, University of Toronto, and \textsuperscript{c} Pharmacogenetics Research Clinic, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ont., Canada

Key Words

Cytokines · Inflammation · Antipsychotic-induced weight gain · Schizophrenia · Side effect

Abstract

Antipsychotic medications (APs), particularly second-generation APs, are associated with significant weight gain in schizophrenia patients. Recent evidence suggests that the immune system may contribute to antipsychotic-induced weight gain (AIWG) via AP-mediated alterations of cytokine levels. Antipsychotics with a high propensity for weight gain, such as clozapine and olanzapine, influence the expression of immune genes, and induce changes in serum cytokine levels to ultimately down-regulate neuroinflammation. Since inflammatory cytokines are normally involved in anorexigenic responses, reduced inflammation has been independently shown to mediate changes in feeding behaviours and other metabolic parameters, resulting in obesity. Genetic variation in pro-inflammatory cytokines is also associated with both general obesity and weight change during AP treatment, and thus, may be implicated in the pharmacogenetics of AIWG. At this time, preliminary data support a cytokine-mediated model of AIWG which may have clinical utility in developing more effective metabolic monitoring guidelines and prevention measures. However, further research is still needed to clearly elucidate the validity of this immune model. This article reviews the evidence implicating inflammatory cytokines in AIWG and its potential clinical relevance.

Introduction

Antipsychotic-induced weight gain (AIWG) is a common side effect which, according to some measures, affects up to 72\% of schizophrenia patients receiving acute or maintenance treatment [1]. AIWG has been documented since the advent of chlorpromazine with reports of steadily increasing weight with treatment that rapidly declines upon drug cessation [2, 3]. AIWG appears to occur more often with second-generation antipsychotics (SGAs) than first-generation antipsychotics (FGAs), and with greater probability for some SGAs than others [4, 5]. In a review by Lett et al. [4], clozapine and olanzapine were identified as conferring the highest risk of weight
gain among SGAs, with quetiapine and risperidone having intermediate risk, and aripiprazole and ziprasidone having minimal risk, according to mean weight change values (fig. 1). While most patients treated with antipsychotics gain weight, some studies also suggest that antipsychotic medications (APs) can induce clinically significant weight loss in up to 10% of patients [6].

AIWG is a leading contributor to AP non-compliance, and a major risk factor for obesity, as well as other metabolic (e.g. dyslipidaemia, hyperglycaemia, diabetes mellitus) and vascular (e.g. cardiovascular and cerebrovascular disease, arterial hypertension, ventricular arrhythmias) abnormalities, and premature mortality [7, 8]. In addition, APs have the potential to exacerbate pre-existing metabolic irregularities that are otherwise observed at lower frequencies and/or severities within untreated schizophrenia [9, 10]. For example, Zhang et al. [9] identified significant increases in subcutaneous and intra-abdominal fat, in addition to elevated levels of leptin, circulating lipids, and non-fasting glucose after 10 weeks of AP treatment in previously untreated schizophrenia patients. In a meta-analysis by Mitchell et al. [10], metabolic irregularities such as obesity (52.7 vs. 26.6%), elevated triglycerides (41.1 vs. 16.9%), low levels of high-density lipoproteins (44.7 vs. 20.4%), high blood pressure (39.7 vs. 24.3%), diabetes mellitus (12.8 vs. 2.1%), and hyperglycaemia (27.8 vs. 6.4%) occurred more frequently in treated as compared to untreated schizophrenia patients, respectively. Beyond psychotic disorders, AIWG has also been observed in other AP-treated psychiatric populations, such as bipolar disorder [11], treatment-resistant major depressive disorder [12], mental retardation and autistic disorder [13], and Tourette’s syndrome [14], suggesting that AIWG occurs independently of schizophrenia as an underlying condition.

Despite these clinically significant metabolic outcomes, the mechanisms implicated in AIWG are not fully understood. Nevertheless, various biological mechanisms have been linked to the orexigenic effects of antipsychotics, including neurotransmitter systems (e.g. serotonergic, histaminergic, adrenergic, dopaminergic), neuropeptides [e.g. leptin, ghrelin, neuropeptide Y (NPY)], and neuroendocrine systems (e.g. insulin, prolactin; for review, refer to Wysokinski and Kloszewska [15]). Recent evidence also suggests that the immune system may at least partially contribute to this metabolic phenotype, particularly via AP-induced alterations of cytokine levels. More specifically, APs have been shown to influence the expression of cytokines to ultimately down-regulate neuroinflammatory signatures [16, 17]. An increase in inflammatory cytokines is normally involved in anorexigenic responses, while reduced inflammation has been independently shown to mediate changes in feeding behaviours and other metabolic parameters which can lead to obesity [18–20]. Genetic variation in pro-inflammatory cytokines is also associated with both general obesity [21–23], and weight change during AP treatment [24], and thus, may be implicated in the pharmacogenetics of AIWG. Although limited research has examined the direct link between cytokines and AIWG, based on these preliminary findings, we propose a cytokine-mediated immune model of AIWG which will be further outlined within this review.

The Role of Cytokines in Energy Homeostasis

Biological Properties of Cytokines

Cytokines are pleiotropic proteins involved in host regulation of both immunological and non-immunological processes, and are classified as either pro-inflammatory or anti-inflammatory in function based on their ability to either augment or suppress the immune response [25]. Cytokines are produced by a variety of cell types within the periphery (e.g. endothelial cells, monocytes/macrophages, dendritic cells, natural killer cells, and T cells) and the central nervous system (CNS; e.g. astro-
cytes, microglia), where they function as chemical messengers [26–28].

In the periphery, cytokines (and other immune factors) are released by phagocytic cells upon infection [27, 29–31], and once the pathogen is cleared, there is a shift toward anti-inflammatory signalling in order to resolve inflammation and restore homeostasis [32]. In the CNS, microglia and astrocytes primarily regulate the initiation and termination of the inflammatory response [33]. Microglia are resident macrophages of the CNS that continuously survey the brain for neuronal damage, plaques, and microves, and provide an immediate response to even minor central pathology [27]. Once activated, microglia engage in a variety of functions including phagocytosis and antigen presentation of invading microbes, secretion of oxidative stress markers like reactive oxygen species (ROS) and reactive nitrogen species, and production of cyclooxygenase (COX)-2, prostaglandin E2, and inflammatory cytokines [34–38]. Although astrocytes can secrete pro-inflammatory mediators, they primarily produce anti-inflammatory factors [38, 39]. Astrocytes also have inhibitory and stimulatory effects on microglia depending on the internal immune state [27].

In addition to centrally produced factors, peripheral cytokines can also access the CNS through multiple humoral pathways that act in parallel, including: (1) passive transport at disrupted regions of the blood-brain barrier (BBB) [40] or through BBB-deficient choroid plexuses and circumventricular organs [41–43], (2) active transport via saturable transport molecules [44, 45], and (3) binding to cerebral endothelial cells to stimulate release of secondary inflammatory messengers [46–48]. Immune information is also transmitted to the brain using rapid neural pathways which activate primary afferent nerve fibres in response to peripheral cytokine release [49–51]. Once immune information from the periphery reaches the brain, it is reconstituted in the CNS via central cytokine release [52].

The immune capabilities of different cytokines are highly redundant, and ultimately lead to the stimulation of multiple cell types and the downstream production of inflammatory mediators [1, 53]. Pro-inflammatory cytokines, such as interleukin (IL)-1, IL-2, IL-6, and tumour necrosis factor alpha (TNF-α) augment the inflammatory cascade by recruiting leukocytes, activating inflammatory cells, and assisting with the elimination of invading pathogens [26, 27]. Anti-inflammatory cytokines, such as IL-4, IL-5, IL-10, IL-1 receptor antagonist (IL-1RA), and soluble IL-2 receptor (sIL-2R), are reciprocally designed to down-regulate inflammation via immunosuppressive functions [38, 54].

Cytokines yield their effects by binding to specific cytokine receptors that are expressed on a variety of peripheral and central cells, and also exist in soluble form [55]. Some receptor subtypes serve as non-functional decoys (e.g. IL-1RII, sIL-2R) [26, 56, 57], while others enhance cytokine activity (e.g. sIL-6R) [26]. Inhibitory effects are also achieved by non-functional receptor antagonists (e.g. IL-1RA) which compete with cytokines for receptor binding sites [56]. Cytokine-receptor complexes are phosphorylated by Janus kinase (JAK) and Src kinases, and signal through pathways like JAK-STAT (signal transducer and activator of transcription), Ras/MAPK (mitogen activated protein kinase), and phosphoinositide-3-kinase (PI-3-kinase) to activate gene transcription and cellular activity [58].

Within this repertoire of immunological functions, cytokines play a key role in regulating energy homeostasis. This occurs primarily through central effects on feeding behaviours and other metabolic outcomes, both for immunological and non-immunological purposes.

Cytokines and Hypothalamic Regulation of Energy Homeostasis

AIWG results from AP-induced disruptions of central and peripheral energy homeostatic pathways, ultimately creating an imbalance favouring energy intake over energy expenditure [59]. Various genetic, neuronal, and hormonal factors are implicated in mediating this association through effects on appetite and satiety signals [60]. Of particular importance are hypothalamic homeostatic circuits which, in controlling food intake and thermoregulation, rely on peripherally released factors to monitor the body’s energy stores and provide appetite-stimulating (orexigenic) or appetite-diminishing (anorexigenic) signals to the CNS [61, 62]. Although signals act at various CNS sites, the pathways converge onto the hypothalamus where they are integrated and cue central neurons to secrete relevant neuropeptides [63, 64]. Inflammatory cytokines, along with leptin and insulin, are anorexigenic factors which function as adiposity signals to provide information on long-term energy stores to the hypothalamus under normal and pathological conditions [15]. To support this role, cytokines have action at central neurons, with particularly high receptor densities localized to the hippocampus and hypothalamus [65, 66]. Cytokines are reciprocally regulated by various centrally released neurotransmitters and neuropeptides [66].

The primary CNS interface for these cytokines is the arcuate nucleus (ARC) of the hypothalamus which, due to an anatomical position near the base of the brain and
Murray and Murray fed ad libitum. Similarly, Wing and Young demonstrated these functions by showing that force-feeding increased leukocyte counts, increased plasma levels of norepinephrine, cortisol, and glucagon, resting energy expenditure, plasma free fatty acid concentration, fat oxidation, and alterations of low-density lipoprotein metabolism. Moreover, cytokines can alter food preferences, as Aubert et al. showed that rats treated with IL-1β, in addition to having a reduced total caloric intake, consumed relatively more carbohydrates and less protein. Taste aversion is also observed following cytokine administration, but this does not appear to be a major component of anorexic action. Nevertheless, anorexigenic responses can be attenuated using cytokine and/or cytokine receptor gene knock-out models, or cytokine antagonism. Tolerance to chronic cytokine administration can develop with consequent restoration of normal food intake, supporting that anorexic effects of cytokines are intended to be short-term. Beyond altering feeding behaviours, cytokines can also influence body weight through effects on energy expenditure such as by inducing changes in body temperature.

The Role of Cytokines in Weight Regulation

The Pathophysiological Role of Cytokines in Weight Regulation during Infection

During times of infection, the anorexigenic effects of inflammatory cytokines, which are typically observed as a reduction in food-motivated behaviours, food intake, and body weight, occur as part of the acute phase response (APR). The APR is an integrated set of immune, endocrine, metabolic, behavioural, and neural alterations that are mounted by the innate immune system upon immediate recognition of an immunological insult. In addition to anorexia, the APR can include fever, lethargy, altered plasma protein concentrations, and increased leukocyte counts. APR reactions form a critically adaptive defence strategy that takes priority over regular homeostatic controls to provide short-term survival benefits to the host. The survival benefits of anorexia can include: (1) reducing food scavenging behaviours to conserve energy and heat, (2) reducing access to food-derived micronutrients that can be used by pathogens to flourish, (3) limiting potentially harmful metabolic APR effects, and (4) promoting apoptosis of infected cells. Murray and Murray demonstrated these functions by showing that force-feeding infected mice to a normal energy intake increased mortality and reduced survival time compared to infected mice fed ad libitum. Similarly, Wing and Young found that acutely starved mice infected with Listeria monocytogenes showed significantly less mortality than fed mice, further demonstrating the survival advantage of anorexic behaviours during times of acute infection.

The Physiological Role of Cytokines in Normal Weight Regulation

During normal fat accumulation and adipocyte enlargement, adipose tissue (particularly within visceral fat) becomes a site of active inflammation as it undergoes molecular and cellular changes, accumulates macrophages, and secretes various immune factors such as inflammatory cytokines. These cytokines subsequently suppress feeding and induce energy expenditure, similar to the anorexigenic effects observed within the APR, via a feedback loop to prevent excessive fat accumulation (i.e., obesity), and thus, maintain homeostatic balance. Once caloric restriction is achieved, it is accompanied by a potent anti-inflammatory effect which can include reduced production of inflammatory cytokines and prosta-glandins, lowered blood lymphocyte counts, and reduced macrophage activation and infiltration into adipocytes.
Central and Peripheral Mechanisms of Cytokine-Induced Anorexia

Peripheral cytokines can stimulate the vagus nerve of the abdomen and gastrointestinal tract which relay signals to the hypothalamus [15]. The vagus nerve may partially mediate anorexigenic effects, as sub-diaphragmatic vagotomy can attenuate suppression of food intake [106] and food-motivated behaviour [106], but not in all cases [107]. Cytokines may work with the peripheral satiety hormone, cholecystokinin (CCK), to stimulate the vagus nerve, as cytokine-induced release of CCK and activation of CCK₂ receptors partially contribute to vagal-mediated hypophagic outcomes [72]. In addition, cytokines like IL-1 and TNF-α act directly on adipocytes to stimulate leptin secretion to suppress food intake [108–112], and influence levels of insulin and glucagon [113]. Further, IL-1, IL-6, and TNF-α reduce stomach muscle contractions to yield gastric stasis (i.e. delayed gastric emptying) which contributes to anorexia by influencing meal size and length of inter-meal intervals [114]. The involvement of inflammatory cytokines within multiple metabolic pathways in the periphery provides some insight into the importance of these adiposity signals in the regulation of energy homeostasis.

In the CNS, cytokines have direct action at hypothalamic neurons in the LHA, PVN, and VMN in mediating feeding behaviours [113]. In support, cytokine mRNA and protein, and cytokine receptors have been found in multiple brain regions including the hypothalamus [115–117], with greatest concentrations in the VMH [69]. In anorexic tumour-bearing rats, IL-1β and IL-1R mRNA are up-regulated in the hypothalamus, and cerebrospinal fluid levels of IL-1 negatively correlate with food intake [69]. Kent et al. [118] demonstrated that direct administration of recombinant IL-1β into the VMN both time- and dose-dependently induced anorexia and weight loss, with food and water consumption reduced by 45 and 30%, respectively. VMN-injected cytokine antagonists can also reverse anorexic outcomes by improving food intake [119, 120]. These data provide further support for the direct involvement of cytokines in the hypothalamic regulation of metabolic activity.

Cytokines can also mediate anorexigenic effects by influencing hypothalamic production of various neurotransmitters and neuropeptides that are relevant to the regulation of food intake. For example, central cytokine administration can reduce levels of NPY, an important orexigenic factor [121]. Sonti et al. [122] observed that NPY administration blocks the anorexic effects of IL-1β and induces feeding in anorexic rats. A similar relationship exists between NPY and interferon-α [82]. Lipopolysaccharide endotoxin and IL-1β have been shown to decrease plasma levels of the orexigenic factor, ghrelin, an effect which can be blocked by administration of exoge-
nous ghrelin, IL-1RA, and the non-steroidal anti-inflammatory drug, indomethacin [123]. In other words, administration of anti-inflammatory factors restores orexigenic signalling in cases where cytokine levels are elevated. Cytokines also interact with other neuropeptides (e.g. POMC-derived peptides, hypocretins/orexins, CART, melanin-concentrating hormone, and AgRP) and neurotransmitters (e.g. dopamine, serotonin, histamine, and norepinephrine) which are involved in regulating food intake [113, 117, 124]. Cytokines are extensively integrated into the hypothalamic metabolic circuit, both regulating and being regulated by various neurotransmitters and neuropeptides, which emphasizes their importance within energy homeostatic pathways.

In addition, secondary cytokine messengers such as prostaglandins, especially prostaglandin E2, and their precursors have been shown to reduce food intake and influence gastrointestinal motility [125–130]. These anorexigenic effects are typically reversible by COX inhibitors like aspirin, flurbiprofen, indomethacin, and paracetamol, which possess anti-inflammatory properties [125, 127]. In support, pre-treatment with COX inhibitors can partially block the anorexic and gastric emptying effects of IL-1 and TNF [114]. Furthermore, cytokines activate the hypothalamic-pituitary-adrenal (HPA) axis [131, 132], and simulate release of corticotropin-releasing hormone (CRH) [133–136] which acts within the brain to reduce food intake [137]. Uehara et al. [138] demonstrated that pre-treatment with CRH-antiserum blocks reductions in food intake subsequent to IL-1β administration. Overall, the involvement of cytokines in the regulation of feeding behaviours appears to be non-linear and highly extensive involving interactions with various regulatory factors and multiple pathway redundancies.

Disruption of Cytokine Signalling in Normal Weight Regulation and Its Implications for Obesity

Obesity as a Consequence of Cytokine Function Disruption

Any perturbations to cytokine-mediated adiposity signalling may cause a shift in weight outcomes. In cases where weight gain is specifically concerned, this outcome may theoretically occur in one of two ways: (1) a developed resistance to inflammatory signalling despite an intact ability to up-regulate cytokine expression, or (2) a blunted ability to up-regulate cytokine expression when needed. In either situation, important information on adiposity reserves fails to be conveyed to the hypothalamus which precludes the initiation of anorexigenic responses, leading to continued fat accumulation, and ultimately, obesity [103]. A recent review by Wang and Ye [139] highlights the critical role of inflammation in the maintenance of energy homeostasis, commenting on how a lack of responsiveness to inflammatory cytokines will skew metabolic outcomes toward obesity while elevated inflammatory activity leads to weight loss and malnutrition, as observed in cancer cachexia.

Inflammatory resistance is observable within general obesity (and metabolic syndrome), where low-grade inflammation is chronically present but with no accompanying reduction in weight [140]. In further support, hyperglycaemia and type 2 diabetes mellitus, which are by-products of obesity-induced/inflammation-induced (particularly via increased levels of TNF-α and IL-6) insulin resistance, are characterized by glucose excretion in the urine, which may be an extreme method to rid the body of surplus energy where more traditional homeostatic mechanisms have failed [103, 141]. Moreover, weight loss in morbidly obese patients yields an improvement in insulin resistance when accompanied by significant reductions in C-reactive protein (CRP) and IL-6 [142].

Similar to inflammatory resistance, a deficit of inflammatory signalling in the face of increased adiposity would yield comparable obesity outcomes. In support, O’Rourke et al. [143] found decreased serum cytokine protein and mRNA levels in peripheral blood mononuclear cells of obese compared to lean patients, which occurred in spite of an intact capacity to up-regulate cytokine expression in response to leptin. These data suggest that obesity may result from reduced inflammatory signalling and/or responsiveness to inflammatory cytokines, which would consequently limit anorexigenic outcomes and weight regulation.

Genetic Knockout Models of Cytokine-Induced Obesity

Various models have tested the association between deficit cytokine production and obesity outcomes using genetic knockout models. Wallenius et al. [19] observed that IL-6-deficient mice (IL-6<sup>−/−</sup>) developed mature-onset obesity accompanied by increased food intake, altered carbohydrate and lipid metabolism, increased leptin levels, and reduced responsiveness to leptin treatment. IL-6 administration was able to partially reverse these effects by lowering body weight and leptin levels, and increasing energy expenditure. However, other research has shown no significant differences between IL-6<sup>−/−</sup> and wild-type
mice on measures of obesity, fasting hyperglycaemia or lipid metabolism [144]. Investigations of IL-1 involvement have yielded similar findings. Garcia et al. [145] found that mice with an IL-1R deficiency (IL-1RI−/−) developed mature-onset obesity relative to wild-type mice by 5 to 6 months of age, with a 20% weight difference emerging by 9 months. IL-1RI−/− mice also developed a 1.5- to 2.5-fold increase in visceral and subcutaneous fat mass, insulin resistance, increased leptin levels and, prior to obesity onset, lower locomotor activity and reduced suppression of body weight and food intake in response to leptin. These developmental data suggest that cytokines exert extensive metabolic effects from relatively early on in life.

Furthermore, McGillicuddy et al. [146] noted that IL-1RI−/− mice developed mature-onset obesity after 6 months despite being fed a low-fat diet, thereby suggesting that obesity outcomes are primarily regulated by internal factors and can occur independent of the environment. Finally, Netea et al. [147] showed that deficiency of IL-18 (IL-18R−/−) in mice led to higher leptin levels, hyperphagia, increased cholesterol and triglyceride concentrations, obesity, and insulin resistance, which could all be partly reversed with central administration of recombinant IL-18. Obesity differences, relative to control mice, first appeared at 6 months of age, with the greatest difference of 38.1% occurring at 12 months. Mice deficient for the IL-18R (IL-18R−/−) also displayed similar obesity and insulin resistance outcomes. Overall, these data suggest that the role of cytokines within metabolic regulation is not limited to food intake and weight outcomes, but rather, includes more global effects on various metabolic parameters. These findings may provide additional insights into the host of metabolic consequences that often occur in tandem with AIWG among AP-treated patients.

There is also an observed synergy between cytokines in yielding weight change effects. Chida et al. [18] found that mice with a combined IL-1 and IL-6 deficiency (IL-1−/−/IL-6−/−) developed obesity by 10 weeks while mice with either an IL-1 or IL-6 knockout remained normal at this age. IL-1−/−/IL-6−/− mice also had significantly higher daily food intake and greater suppression of anorexic effects after peripheral IL-1 administration. These results provide further support for the redundancies in cytokine metabolic pathways, as functional blockade of one cytokine pathway does not necessarily lead to global orexigenic effects.

In addition to inflammatory cytokines, anti-inflammatory factors can also yield considerable, yet opposing effects on weight change outcomes. IL-1RA−/− mice, in which excess IL-1 signalling may occur, have a lean phenotype through impaired body fat accumulation and lipid storage, and resistance against the obesity-inducing effects of both monosodium glutamate and a high-fat diet [148]. Additional studies of IL-1RA−/− mice revealed a lean phenotype based on reduced fat mass, dysfunctional adipogenesis, and increased energy expenditure, in addition to reduced body weight relative to heterozygote IL-1RA+/− littermates [149, 150]. Thus, anti-inflammatory cytokines appear to work in concert with inflammatory cytokines to indirectly regulate homeostatic balance through their antagonizing effects on pro-inflammatory activity.

Cytokine Genetic Variants and Obesity

Genetic investigations involving polymorphisms in cytokine genes show an association with obesity in humans. Andersson et al. [151] found that the 3′ untranslated region variant rs4252041 (C>T) of the IL-1RA gene was associated with lower total and regional fat mass, total fat percent (%) and body mass index (BMI) in men. Um et al. [152] found two IL-1α polymorphisms, C-889T (rs1800587) and G+4845T (rs17561), that were associated with an increase in BMI in obese healthy women. Lee et al. [153] investigated the IL-1β +3953 (rs1143634) variant site, finding a higher frequency of the T (CT/TT), or high transcriptional, allele among lean BMI (<25) versus overweight BMI (25–29) females. The same locus was tested by Manica-Cattani et al. [21], similarly finding a higher T allele frequency in non-overweight than overweight and obese groups. Strandberg et al. [154] also tested the +3953 variant but against body fat mass in men. Results showed that carriers of the T allele had significantly lower total fat mass, in addition to reduced arm, leg, and trunk fat.

The IL-6 gene has also been implicated in metabolic outcomes. Additional investigations by Strandberg et al. [155] found an association for both the IL-1β −31T>C (rs1143627) and IL-6 −174G>C (rs1800795) polymorphisms with total and regional fat mass in elderly men. Interestingly, the IL-6 −174C variant, which produces less IL-6, has been associated with higher BMI and risk of obesity-related metabolic indices like insulin resistance and high systolic blood pressure [156, 157], while the −174G variant has been associated with a lean phenotype, low waist circumference, and low concentrations of insulin or glucose [22]. Andersson et al. [158] found the IL-6 rs10242595*A variant to be associated with low BMI and total body fat mass, and smaller regional fat masses. In addition, the IL-6 promoter polymorphism, rs2069827 G>T, is associated with elevated early-
adulthood BMI, baseline BMI, and waist circumference in men and women, separately [159]. Woford et al. [160] studied multiple polymorphisms across the IL-6R gene (rs4845623 T>C, c_1981308_10 T>C, rs2228145 T>G, c_1158918_10 G>C, rs2229328 T>C) finding that carriers of the variant allele for these sites had a higher mean BMI compared to those with the wild-type allele when tested among non-diabetic Pima Indians.

In addition to research examining general obesity outcomes, previous investigations by our own study team have identified multiple cytokine polymorphisms associated with AIWG. We found that variant sites across the IL-1β gene, specifically rs16944*GA, rs1143634*G, and rs4849127*A, were associated with greater AIWG in schizophrenia patients [161]. Our analyses further identified epistatic effects between IL-1β (rs13032029, rs16944) and the anorexigenic neurotrophin, brain-derived neurotrophic factor (BDNF), specifically the Val66Met variant, in predicting AIWG outcomes. Epistatic interactions were also demonstrated between IL-6 rs2069837 and BDNF Val66Met [161]. Furthermore, an expansion of GWAS results from the Genetic Investigation of ANThropometric Traits (GIANT) identified associations between BMI and variants across genes associated with the MAPK pathway, which has been implicated in cytokine signaling [162]. Despite the availability of genetic data, interpretation of these results is limited by the absence of functional data which are needed to determine the direction of association. Nevertheless, these results, which highlight the significant influence of genetic variability across cytokine genes on weight gain outcomes, suggest that AIWG may partially derive from a genetic susceptibility.

### Antipsychotic-Induced Disruption of Cytokine Signalling and the AIWG Side Effect

#### Linking the Anti-Inflammatory Properties of Antipsychotics to AIWG

Several studies suggest that APs have immunomodulatory properties (table 1), particularly anti-inflammatory effects, which may contribute to their clinical efficacy. Long-term treatment with APs has primarily been shown to increase expression of anti-inflammatory mediators (e.g. sIL-1RA, sIL-2R, and IL-10) while simultaneously reducing pro-inflammatory markers (e.g. IL-1β, IL-2, IL-6, sIL-6R, and TNF-α) in the periphery and CNS [17, 27, 163]. Despite these main trends, a meta-analysis of cytokine alterations in schizophrenia patients proposed that only state marker cytokines such as IL-1β and IL-6 are responsive to AP treatment, while trait makers such as interferon-γ, TNF-α, and sIL-2R, remain unchanged [164]. The reverse relationship has also been demonstrated with levels of inflammatory cytokines increasing subsequent to AP treatment [16]. However, these results should be cautiously interpreted as the use of serological methodology can compromise data outcomes through the introduction of various confounds which can alter peripheral cytokine expression. APs have also been shown to reduce microglia activation and release of nitric oxide and ROS [165–167], and increase levels of S100B (a calcium- and zinc-binding protein which serves as a marker for astrocyte activity) in some [168, 169] but not all cases [170]. Additional support for the anti-inflammatory properties of APs is derived from reports of AP efficacy in treating inflammation-based conditions such as tuberculosis/mycobacterial infections [171], and rheumatoid arthritis [172]. APs may mediate these effects by suppressing production of pro-inflammatory cytokines and nitric oxide from activated microglia [31, 34].

The alteration of cytokine systems by APs may have secondary consequences on normal adiposity signalling by disrupting inflammatory cytokine release. If levels of inflammatory cytokines are suppressed, information on long-term energy stores may be compromised, thereby preventing hypothalamic circuits from restoring energy homeostasis via anorexigenic responses. This may ultimately lead to a continued accumulation of adiposity demonstrated as weight gain and/or obesity (fig. 2). Moreover, SGAs have more potent anti-inflammatory properties relative to FGAs [27, 173], which provides support for data trends which consistently implicate SGAs in having a greater propensity toward AIWG as compared to FGA treatments.

<table>
<thead>
<tr>
<th>Immune biomarker</th>
<th>Primary direction of change</th>
<th>Citations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inflammatory cytokines* (e.g. IL-1, IL-2, IL-6, IL-6R, TNF-α)</td>
<td>↓</td>
<td>17, 27, 163</td>
</tr>
<tr>
<td>Anti-inflammatory cytokines* (e.g. sIL-1RA, sIL-2R, IL-10)</td>
<td>↑</td>
<td>17, 27, 163</td>
</tr>
<tr>
<td>S100B</td>
<td>↑</td>
<td>168, 169</td>
</tr>
<tr>
<td>Microglia activation</td>
<td>↓</td>
<td>165, 166</td>
</tr>
<tr>
<td>Nitric oxide release</td>
<td>↓</td>
<td>165, 166</td>
</tr>
<tr>
<td>ROS</td>
<td>↓</td>
<td>167</td>
</tr>
</tbody>
</table>

* In both the periphery and CNS.
Preliminary Evidence Supporting a Cytokine-Mediated Model of AIWG

There is a growing body of evidence that supports the role of cytokine dysfunction in metabolic disturbances, like AIWG, in schizophrenia. A recent genetic analysis by Chase et al. [174] identified concurrent dysregulation of obesogenic (e.g. peroxisome proliferator-activated receptor, sterol regulatory element binding transcription factor 1) and immunogenetic (e.g. IL-6, TNF-α, CCAAT/enhancer-binding protein-α) gene expression in schizophrenia patients. An additional analysis of blood mononuclear cells further identified a significant difference between obese and non-obese schizophrenia patients on measures of inflammatory cytokines, in addition to serum levels of leptin and adiponectin [175].

In considering the proposed immunomodulatory properties of APs, it is plausible that immune factors contribute to AIWG. This theory has received some attention in recent years, starting with Klunge et al. [176] who proposed that the effects of clozapine and olanzapine on weight gain may be closely related to their effects on cytokine networks. In this study, 30 patients diagnosed with schizophrenia, schizophreniform or schizoaffective disorder were randomized to either clozapine (mean modal dose: 266.7 ± 77.9 mg) or olanzapine (21.2 ± 2.5 mg) treatment for 6 weeks. Data were longitudinally collected on BMI, and plasma levels of leptin and cytokines which included TNF-α, soluble TNF receptor (sTNFR)-1, sTNFR-2, IL-6, and sIL-2R. All cytokine levels were found to significantly change over time, with the exception of IL-6 and sTNFR-1 among olanzapine-treated patients, thereby suggesting treatment-specific effects on cytokine systems. In addition, TNF-α, sTNFR-1, sTNFR-2, and sIL-2R levels correlated with BMI after 6 weeks of treatment.

Similarly, Song et al. [177] observed significant alterations in serum levels of IL-1β, IL-6, and TNF-α, in addition to body weight, over 6 months of risperidone treatment in 62 drug-naïve first-episode schizophrenia patients. In fact, patients who experienced clinically significant (>7%) weight gain by the end of treatment had higher levels of all cytokine markers compared to patients who gained <7% of weight. However, the data from these last two studies are limited by their relatively small sample sizes. Therefore, additional cytokine analyses in larger clinical samples are required to more clearly elucidate the cytokine-AIWG relationship.

Klemettila et al. [178] relied on a larger sample of 190 treatment-resistant schizophrenia patients who were administered clozapine. Results showed that levels of IL-1RA and CRP were associated with obesity after controlling for age and smoking status, as was IL-6 specifically among female patients. Together, these data suggest both age- and gender-dependent cytokine effects which show that the cytokine-AIWG relationship can be affected by patient-related variables. Overall, these results indicate that administration of AP treatment yields alterations of cytokine levels which occur in tandem with changes to weight outcomes. Thus, these findings provide preliminary support for a cytokine-mediated immune model of AIWG.

Conclusions

At this time, preliminary evidence suggests that the immune system may partially contribute to AIWG via AP-mediated alterations of cytokine levels. Antipsychotics with a high propensity for weight gain likely yield these effects through their documented ability to decrease pro-inflammatory cytokine production while increasing levels of anti-inflammatory mediators to ultimately down-regulate neuroinflammation. In considering that anorexigenic outcomes are mediated via increased levels of inflammatory cytokines, these AP-induced alterations create an internal inflammatory milieu which may disrupt adiposity signalling in favour of fat accumulation. As documented within this review, obesity outcomes are associated with a reduced production and/or responsiveness to inflammatory cytokines. Hence, reduced inflammatory cytokine signalling resulting from AP administration has the potential to yield AIWG, as further supported by serological data in AP-treated schizophrenia patients. Based on the available literature, the inflammatory cytokines IL-1, IL-6, and TNF-α may be particularly key players in mediating the relationship between APs and AIWG.

Based on this hypothesized model, it may be advisable for clinicians to routinely monitor patients for changes in blood levels of inflammatory mediators, particularly IL-1, IL-6, and TNF-α, in addition to completing standard metabolic profiling. However, clinical monitoring of peripheral cytokine levels remains, at this preliminary stage, only a potential screening tool that would require further research to enhance its clinical application, particularly by addressing the issues of situational confounds of serological methodology, identifying a plasma level range for healthy versus pathological plasma cytokine concentrations, and generating clinical guidelines on how to interpret blood reports. This information may also inform new cytokine drug targets for AIWG in AP-treated popula-
tions. However, in considering that reduced neuroinflammation may mediate therapeutic response to APs, such a targeted approach to improving AIWG will need to be balanced against secondary effects on clinical efficacy. Cytokine data may also have clinical application in designing predictive biomarker screens for AIWG which may include serological quantification of circulating cytokines in the blood or cerebrospinal fluid, or high-throughput genetic analyses of cytokine polymorphisms. However, since details characterizing the relationship between cytokines and AIWG have yet to be clearly elucidated, further research is required before more effective clinical guidelines and prevention measures can be developed.

Acknowledgements

T.M.F. is a recipient of a Canadian Institutes of Health Research (CIHR) 2012 Frederick Banting and Charles Best Masters Award. S.H.K. has received grant/research support from Ontario Brain Institute, Brain Canada and CIHR. D.J.M. has received the following: CIHR operating grant (Genetics of Antipsychotics Induced Metabolic Syndrome, MOP 89853), Brain & Behaviour Research Foundation NARSAD Independent Investigator Award, CIHR Michael Smith New Investigator Salary Prize for Research in Schizophrenia, Early Researcher Award from the Ontario Ministry of Research and Innovation, and a New Investigator Fellowship from the Ontario Mental Health Foundation (OMHF). The content of this paper is solely the responsibility of the authors and does not necessarily represent the official views of these organizations.

Disclosure Statement

We confirm this paper describes original work that has not been published elsewhere and is not under consideration by another journal. S.H.K. has received research support from Lundbeck, St. Jude Medical, Bristol-Myers Squibb, and Clera Inc. He has received speaking fees from and/or is a member of an advisory board for Eli Lilly, Janssen Inc., Lundbeck, Lundbeck Institute, Pfizer, Bristol Myers Squibb, and Servier.

References

<table>
<thead>
<tr>
<th>Author(s)</th>
<th>Reference</th>
<th>Page Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Barton GM</td>
<td>A calculated response: control of inflammation in the CNS</td>
<td>11</td>
</tr>
<tr>
<td>Bergink V, Gibney SM, Drexhage HA</td>
<td>Autoimmune response: genetic association yields new sequence variants at</td>
<td>111–118</td>
</tr>
<tr>
<td>Ishii KJ, Koyama S, Nakagawa A, Coban C, Akira S</td>
<td>Role of immune parameters in the rat</td>
<td>367–373</td>
</tr>
<tr>
<td>Harkin A, Versnel MA, Drexhage HA</td>
<td>The immune theory of psychiatric diseases: a key role for activated microglia and circulating monocytes</td>
<td>404–415</td>
</tr>
<tr>
<td>Dong V, Benveniste EN</td>
<td>Immune function of astrocytes</td>
<td>416–420</td>
</tr>
<tr>
<td>Banks WA</td>
<td>Blood-brain barrier transport of cytokines: a mechanism for neuropathology</td>
<td>421–425</td>
</tr>
<tr>
<td>Quan N, Whiteside M, Herkenham M</td>
<td>Immune response to lipopolysaccharide</td>
<td>439–443</td>
</tr>
<tr>
<td>Johnson AK, Gross PM</td>
<td>Sensory circumventricular organs and brain homeostatic pathways</td>
<td>454–458</td>
</tr>
<tr>
<td>Nansho RF, Kanso YK, Terada N, Dantzer R, Bluthe RM, Kelley KW</td>
<td>Neural and humoral pathways of communication from the immune system to the brain: parallel or convergent?</td>
<td>459–463</td>
</tr>
<tr>
<td>Konsman JP, Parnet P, Dantzer R</td>
<td>Cytokine-induced sickness behaviour: mechanisms and implications</td>
<td>464–468</td>
</tr>
<tr>
<td>Anisman H</td>
<td>An assessment of the effects of central interleukin-1beta, -2, -4, and -6, and tumor necrosis factor-alpha</td>
<td>474–478</td>
</tr>
<tr>
<td>Kretzberg GW</td>
<td>Microglia: a sensor for pathological events in the CNS</td>
<td>479–483</td>
</tr>
<tr>
<td>Banati RB, Gehrmann J, Schubert P, Kretzberg GW</td>
<td>Cytotoxicity of microglia</td>
<td>484–488</td>
</tr>
<tr>
<td>Bergink V, Gibney SM, Drexhage HA</td>
<td>Autoimmunity, inflammation, and psychosis: a search for peripheral markers</td>
<td>489–493</td>
</tr>
<tr>
<td>Najjar S, Pearlman DM, Alper K, Najjar A, Devinsky O</td>
<td>Neuroinflammation and psychiatric illness</td>
<td>494–498</td>
</tr>
</tbody>
</table>

Cytokines in Antipsychotic-Induced Weight Gain

Mol Neuropsychiatry 2016;2:1–14
DOI: 10.1159/000441521
Cytokines in Antipsychotic-Induced Weight Gain


Cytokine Netw 2006;17:4–12.


